Current and novel cardiac support therapies

Current Heart Failure Reports

Volumn 6, Issue 1, 2009, Pages 19-27

  Jugdutt, Bodh I ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INOTROPIC AGENT; LEAD; MATRIX METALLOPROTEINASE; MESSENGER RNA; NITINOL; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; TISSUE INHIBITOR OF METALLOPROTEINASE;

AORTA BALLOON; ARTIFICIAL HEART PACEMAKER; ASSISTED CIRCULATION; CARDIOPULMONARY BYPASS; CELL THERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DEVICE INFECTION; EXTRACELLULAR MATRIX; EXTRACORPOREAL OXYGENATION; GENE ACTIVATION; HEART ASSIST DEVICE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE SIZE; HEART MUSCLE REVASCULARIZATION; HEART SURGERY; HEART TRANSPLANTATION; HEART VENTRICLE REMODELING; HUMAN; MITRAL VALVE REPAIR; OUTCOME ASSESSMENT; PACEMAKER FAILURE; PATHOPHYSIOLOGY; REVIEW; ST SEGMENT ELEVATION; SURVIVAL RATE; SURVIVAL TIME; TISSUE ENGINEERING; TREATMENT INDICATION;

FEMALE; FORECASTING; HEART FAILURE; HEART TRANSPLANTATION; HEART, ARTIFICIAL; HEART-ASSIST DEVICES; HUMANS; MALE; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 62649113431     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-009-0005-9     Document Type: Review

References (59)

1. Hunt SA: ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005, 46: e1-e82.
2. Mann DL: Pathophysiology of heart failure. In Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, edn 7. Edited by Libby P, Bonow RO, Man DL, Zipes DP. Philadelphia: Saunders Elsevier; 2008:541-560.
3. Lowes BD, Gilbert EM, Abraham WT, et al.: Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents. N Engl J Med 2002, 346: 1357-1365.
4. Jugdutt BI: Ventricular remodeling postinfarction and the extracellular collagen matrix: When is enough enough? Circulation 2003, 108: 1395-1403.
5. Jugdutt BI: Remodeling of the myocardium and potential targets in the collagen degradation and synthesis pathways. Curr Drug Targets, Cardiovasc Haematol Disord 2003, 3: 1-30.
6. McCarthy PM: Surgical management of heart failure. In Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Edited by Libby P, Bonow RO, Man DL, Zipes DP. Philadelphia: Saunders Elsevier; 2008:665-684.
7. Taylor DO, Edwards LB, Boucek MM, et al.: Registry of the International Society for Heart and Lung Transplantation: Twenty-fourth official adult heart transplant report-2007. J Heart Lung Transplant 2007, 26: 769-781.
8. Goldstein DJ, Smego D, Michler RE: Surgical aspects of congestive heart failure. Heart Fail Rev 2006, 11: 171-92.
9. Wellnhofer E, Olariu A, Klein C: Magnetic resonance lowdose dobutamine test is superior to SCAR quantification for the prediction of functional recovery. Circulation 2004, 109: 2172-2174.
10. Aziz T, Burgess M, Rahman AN, et al.: Cardiac transplantation for cardiomyopathy and ischemic heart disease: Differences in outcome up to 10 years. J Heart Lung Transplant 2001, 20: 525-533.
11. Copeland JG, Smith RG, Arabia FA, et al.: Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med 2004, 351: 859-867.
12. Patel SM, Throckmorton AL, Untaroiu A, et al.: The status of failure and reliability testing of artificial blood pumps. ASAIO J 2005, 51: 440-451.
13. Abiomed. Available at http://www.abiomed.com/products/ heart_replacement.cfm. Accessed October 2008.
14. Phillips HR, O'Connor CM, Rogers J: Revascularization for heart failure. Am Heart J 2007, 153(4 Suppl): 65-73.
15. Carluccio E, Biagioli P, Alunni G, et al.: Patients with hibernating myocardium show altered left ventricular volumes and shape, which revert after revascularization: Evidence that dyssynergy might directly induce cardiac remodeling. J Am Coll Cardiol 2006, 47: 969-977.
16. Allman KC, Shaw LJ, Hachamovitch R, Udelson JE: Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: A meta-analysis. J Am Coll Cardiol 2002, 39: 1151-1158.
17. Tarakji KG, Brunken R, McCarthy PM, et al.: Myocardial viability testing and the effect of early intervention in patients with advanced left ventricular systolic dysfunction. Circulation 2006, 113: 230-237.
18. Doenst T, Velazquez EJ, Beyersdorf F, et al.: To STICH or not to STICH: we know the answer, but do we understand the question? J Thorac Cardiovasc Surg 2005, 129: 246-249.
19. Di Sciascio G, Patti G, D'Ambrosio, Nusca A: Coronary stenting in patients with depressed left ventricular function: Acute and long-term results in a selected population. Catheter Cardiovasc Interv 2003, 59: 429-433.
20. Beanlands R, Nichol G, Ruddy TD, et al.: Evaluation of outcome and cost effectiveness using an FDG PET-guided approach to management of patients with coronary disease and severe left ventricular dysfunction (PARR-2): rational, design, and methods. Control Clin Trials 2003, 24: 776-794.
21. Patel JB, Borgeson DD, Barnes ME, et al.: Mitral regurgitation in patients with advanced systolic heart failure. J Card Fail 2004, 10: 285-291.
22. Badhwar V, Bolling SF: Mitral valve surgery in the patient with left ventricular dysfunction. Semin Thorac Cardiovasc Surg 2002, 14: 133-136.
23. Gangemi JJ, Tribble CG, Ross SD, et al.: Does the additive risk of mitral valve repair in patients with ischemic cardiomyopathy prohibit surgical intervention? Ann Surg 2000, 231: 710-714.
24. Di Donato M, Sabatier M, Dor V, et al.: Effects of the Dor procedure on left ventricular dimension and shape and geometric correlates of mitral regurgitation one year after surgery. J Thorac Cardiovasc Surg 2001, 121: 91-96.
25. Athanasuleas CL, Buckberg GD, Stanley AW, et al.: Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation. J Am Coll Cardiol 2004, 44: 1439-1445.
26. Adams JD, Fedoruk LM, Tache-Leon CA, et al.: Does preoperative ejection fraction predict operative mortality with left ventricular restoration? Ann Thorac Surg 2006, 82: 1715-1719.
27. Parolari A, Naliato M, Loardi C, et al.: Surgery of left ventricular aneurysm: A meta-analysis of early outcomes following different reconstruction techniques. Ann Thorac Surg 2007, 83: 2009-2016.
28. Naka Y, Rose EA: Assisted circulation in the treatment of heart failure. In Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Edited by Libby P, Bonow RO, Man DL, Zipes DP. Philadelphia: Saunders Elsevier; 2008:685-696.
29. Rose EA, Gelijns AC, Moskowitz AJ, et al.: Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001, 345: 1435-1443.
30. Stevenson LW, Miller LW, Desvigne-Nickens P, et al.: Left ventricular assist device as destination for patients undergoing intravenous inotropic therapy: A subset analysis from REMATCH (randomized evaluation of mechanical assistance in treatment of chronic heart failure). Circulation 2004, 110: 975-981.
31. Thoratec. Available at http://www.thoratec.com/vad-trialsoutcomes/ index.aspx. Accessed October 2008.
32. Jarvik Heart: Clinical trials. Available at http://www.jarvikheart.com/ basic.asp?id=33. Accessed October 2008.
33. MedGadget: CentriMag right ventricular assist device gets humanitarian device exemption. Available at http://medgadget.com/archives/2008/10/centrimag_right_ventricular_ assist_device_gets_humanitarian_device_exemption.html Accessed October 2008.
34. Jugdutt BI, Butler C: Ventricular unloading, tissue angiotensin II, matrix modulation, and function during left ventricular assist device support. J Am Coll Cardiol 2007, 49: 1175-1177.
35. Klotz S, Danser AH, Foronjy RF, et al.: The impact of angiotensin-converting enzyme inhibitor therapy on the extracellular collagen matrix during left ventricular assist device support in patients with end-stage heart failure. J Am Coll Cardiol 2007, 49: 1166-1174.
36. Hon JK, Yacoub MH: Bridge to recovery with the use of left ventricular assist device and clenbuterol. Ann Thorac Surg 2003, 75(6 Suppl): S36-S41.
37. Abraham WT, Fisher WG, Smith AL, et al.: Cardiac resynchronization in chronic heart failure: N Engl J Med 2002, 346: 1845-1853.
38. McAlister FA, Ezekowitz J, Hooton N, et al.: Cardiac resynchronization therapy for patients with left ventricular systolic dysfunction: A systemic review. JAMA 2007, 297: 2502-2514.
39. Young JB, Abraham WT, Smith AL, et al.: Combined cardiac resynchronization and implantable cardioversion defibrillation in advanced chronic heart failure: The MIRACLE ICD Trial. JAMA 2003, 289: 2685-2694.
40. St John Sutton MG, Plappert T, Abraham WT, et al.: Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003, 107: 1985-1990.
41. Jugdutt BI: Prevention of ventricular remodelling post myocardial infarction: Timing and duration of therapy. Can J Cardiol 1993, 9: 103-114.
42. Acorn Cardiovascular. Available at http://www.acorncv.com/about_acorn. Accessed October 2008.
43. Sabbah HN, Sharov VG, Gupta RC, et al.: Reversal of chronic molecular and cellular abnormalities due to heart failure by passive mechanical ventricular containment. Circ Res 2003, 93: 1095-1101.
44. Sabbah HN: Global left ventricular remodeling with the Acorn Cardiac Support Device: Hemodynamic and angiographic findings in dogs with heart failure. Heart Fail Rev 2005, 10: 109-115.
45. Mann DL, Acker MA, Jessup M, et al.: Clinical evaluation of the CorCap Cardiac Support Device in patients with dilated cardiomyopathy. Ann Thorac Surg 2007, 84: 1226-1235.
46. Starling RC, Jessup M, Oh JK, et al.: Sustained benefits of the CorCap Cardiac Support Device on left ventricular remodeling: Three year follow-up results from the Acorn clinical trial. Ann Thorac Surg 2007, 84: 1236-1242.
47. McGee EC, Gillinov AM, McCarthy PM: Reverse ventricular remodeling: mechanical options. Curr Opin Cardiol 2006, 21: 215-220.
48. Magovern JA: Experimental and clinical studies with the Paracor cardiac restraint device. Semin Thorac Cardiovasc Surg 2005, 17: 364-368.
49. Fukamachi K, McCarthy PM: Initial safety and feasibility clinical trial of the myosplint device. J Card Surg 2005, 20: S43-S47.
50. Grossi EA, Saunders PC, Woo YJ, et al.: Intraoperative effects of the coapsys annuloplasty system in a randomized evaluation (RESTOR-MV) of functional ischemic mitral regurgitation. Ann Thorac Surg 2005, 80: 1706-1711.
51. Grossi EA, Woo YJ, Schwartz CF, et al.: Comparison of Coapsys annuloplasty and internal reduction mitral annuloplasty in the randomized treatment of functional ischemic mitral regurgitation: Impact on the left ventricle. J Thorac Cardiovasc Surg 2006, 131: 1095-1098.
52. Dimmeler S, Mann DL, Zeiher A: Emerging therapies and strategies in the treatment of heart failure. In Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. Edited by Libby P, Bonow RO, Man DL, Zipes DP. Philadelphia: Saunders Elsevier; 2008:697-715.
53. Dib N, Michler RE, Pagani FD, et al.: Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy: Four-year follow-up. Circulation 2005, 112: 1748-1755.
54. Abdel-Latif A, Bolli R, Tleyjeh IM, et al.: Adult bone marrow-derived cells for cardiac repair: A systematic review and meta-analysis. Arch Intern Med 2007, 167: 989-997.
55. Leor J, Aboulafia-Etzion S, Dar A, et al.: Bioengineered cardiac grafts: a new approach to repair the infarcted myocardium? Circulation 2000, 102(19 Suppl 3): III56-III61.
56. Christman KL, Fang Q, Yee MS, et al.: Enhanced neovasculature formation in ischemic myocardium following delivery of pleiotrophin plasmid in a biopolymer. Biomaterials 2005, 26: 1139-1144.
57. Davis ME, Hsieh PC, Takahashi T, et al.: Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci U S A 2006, 103: 8155-8160.
58. Landa N, Miller L, Feinberg MS, et al.: Effect of injectable alginate implant on cardiac remodeling and function after recent and old infarcts in rat. Circulation 2008, 117: 1388-1396.
59. Sabbah HN: Reconstruction of the failing left ventricle with intramyocardial injections of biopolymers [abstract]. J Heart Dis 2008, 6: 92.